Nexalis Therapeutics Limited has released a press release.
Update on Funding Facility and Clinical Program
Earlier from Nexalis Therapeutics
- Binding Letter of Intent to replace existing $53m facility
- Suspension from Quotation
- Mar26 Appendix 4C Cash Flow Report
- Significant Milestone - First Patient Screened IRX-211 Ph2